Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05377905 · ClinicalTrials.gov registry record · Phase 1
Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)
A Phase 1 study of Cutaneous Squamous Cell Carcinoma and Skin Cancers - Squamous Cell Carcinoma, sponsored by Falo, Louis, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT05377905 is a Phase 1 study of Cutaneous Squamous Cell Carcinoma and Skin Cancers - Squamous Cell Carcinoma that is actively recruiting participants, run by Falo, Louis, MD. The registered enrollment target is 48 participants, below the 90-participant average among 18 other Cutaneous Squamous Cell Carcinoma trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05377905, a Phase 1 study of Cutaneous Squamous Cell Carcinoma and Skin Cancers - Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Falo, Louis, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test a new method of experimental treatment for cutaneous squamous cell skin cancer, using small adhesive-like patches (a micro-needle applicator or MNA for short), which have dozens of very small micro-needles loaded with extremely low doses of doxorubicin, a chemotherapy agent. The overall goal of this study is to test the safety and effectiveness of these patches. The investigators have established the highest tolerated dose at 50 micrograms in a previous study for a different type of cancer that affects the skin. The investigators will thoroughly evaluate the skin where the patches are applied.
Conditions Studied
Interventions
- DRUG Microneedle Array Doxorubicin (MNA-D)
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-09-13 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05377905
The ClinicalTrials.gov registry entry for NCT05377905 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 18 other Cutaneous Squamous Cell Carcinoma trials with a reported enrollment target (47% lower). The listed sponsor is Falo, Louis, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cutaneous Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Microneedle Array Doxorubicin (MNA-D) is the first listed.
NCT05377905 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05377905 about?
NCT05377905 is a clinical study titled "Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)". The purpose of this study is to test a new method of experimental treatment for cutaneous squamous cell skin cancer, using small adhesive-like patches (a micro-needle applicator or MNA for short), which have dozens of very small micro-needles loaded with extremely low doses of doxorubicin, a chemoth...
What is the current status of trial NCT05377905?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2023-09-13. Estimated completion is 2026-12-31.
What conditions does trial NCT05377905 study?
This clinical trial studies the following conditions: Cutaneous Squamous Cell Carcinoma, Skin Cancers - Squamous Cell Carcinoma.
What interventions are being tested in trial NCT05377905?
The interventions under investigation include: Microneedle Array Doxorubicin (MNA-D) (DRUG).
Who is sponsoring clinical trial NCT05377905?
This trial is sponsored by Falo, Louis, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05377905 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
ACTIVE NOT RECRUITING · Phase 1
-
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Cutaneous Squamous Cell Carcinoma
All registered trials for this condition
Skin Cancers - Squamous Cell Carcinoma
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.